Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
27 June 2022 - 10:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE
ACT OF 1934
For the month of June 2022
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(formerly Auris Medical Holding
Ltd.)
(Exact name of registrant
as specified in its charter)
Clarendon House, 2 Church
Street
Hamilton HM 11, Bermuda
(Address of principal executive
office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
INCORPORATION BY REFERENCE
This Report on Form 6-K, including the exhibit to
this Report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-228121, 333-249347, 333-261127
and 333-264298)
and Form S-8 (Registration Number 333-232735 and 333-252141)
of Altamira Therapeutics Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents
or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Altamira Therapeutics Ltd. |
|
|
Date: June 27, 2022 |
By: |
/s/
Thomas Meyer |
|
|
Name: |
Thomas Meyer |
|
|
Title: |
Chief Executive Officer |
EXHIBIT INDEX
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Auris Medical Holding AG (NASDAQ): 0 recent articles
More Altamira Therapeutics Ltd. News Articles